drugset / Trial / NCT03978364
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC
RandomizedParallel-groupOpen-labelTreatment
Summary
evaluate the clinical efficacy and safety of azacitidine combined with HAG regimen for patients with int/high -risk MDS and AML-MRC with less than 30% blasts compared with azacitidine
Timeline
- Start
- 2019-06-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Comparator | Homoharringtonine | Small molecule | 3 mg/m2 | Intravenous |